SNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
SOLIGENIX, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.34−0.01 (-2.66%)
Close on Oct 19, 2026
- Market cap
- $5.48M
- P/E (TTM)
- –
- Dividend yield
- –
SOLIGENIX, INC. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialized BioTherapeutics | – | – | – | – | – | – | $0 | $0 | $2.34K | $117.03K | $171.25K | $0 | – | – |
| Public Health Solutions | – | – | – | – | – | – | – | – | – | – | $73.56K | $130.44K | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public Health Solutions | -$2.85K | -$2.66K | -$22.65K | -$2.64K | -$4.24K | -$59.24K | -$88.92K | -$57.61K | -$62.05K | -$46.00K | -$9.89K | -$24.82K | -32.7% |
| Specialized BioTherapeutics | -$871.51K | -$1.69M | -$2.12M | -$1.53M | -$1.55M | -$1.78M | -$2.39M | -$834.65K | -$283.21K | -$860.60K | -$584.87K | -$705.75K | -43.8% |
By product or service
By region
From the segment and revenue-disaggregation notes of Soligenix's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.